Conference Speakers
Cultural Speakers
Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.
At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:
X
Dr. Speakers Full Name
Speaker Credentials
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization and in 2008 sat for and passed the exam administered by the International Board of Lactation Consultant Examiners. As an International Board Certified Lactation Consultant, she now
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization text text text text more name mulder first became interested in breastfeeding in the year 2000, when she became.
X
Abstract: Breastfeeding mothers may turn to formula and/or bottles for many
reasons. Some supplementing with formula by bottle when they reach out for help, and for some moms,
supplementing by alternative methods may be very overwhelming. Some moms need or choose a combination
of breast milk and formula and others may decide to give occasional or regular bottles of expressed
milk. Whatever the reason, as health care professionals helping a mother to breastfeed, it is our
job to be able to help her to reach her own personal goals even when she needs, or chooses to use,
bottles or formula. Learn about baby-led bottle feeding and why it's so important, different types
of formula, their uses and how to prepare them, and how this all fits in with the WHO code and our
code of professional conduct.
View Full Presentation Information & Scheduling
Dr. Speakers Full Name
Speaker Credentials
Speakers (5191)
Professor Isabelle Opitz is Director of the Department of Thoracic Surgery and Chair of the Lung Cancer Center, University Hospital Zurich, Switzerland. Beside her general thoracic surgery activity, other interests are the treatment of pleural mesothelioma, pulmonary endarterectomy and transplantation. She was awarded with several national and international prizes and has acquired more than 6 million Euro grant for her own research. She is an author of more than 100 original articles, multiple reviews, and book chapters. She is a member of numerous societies and currently treasurer and president elect of the European Society of Thoracic Surgery where she has a leading function in the Learning Affairs Committee. For IASLC she is a representative of the task force MPM and a member of the MPM and N-descriptor staging sub-committee.
Published in
Speakers
Lauren Averett Byers, MD, MS is an Associate Professor in the Department of Thoracic and Head and Neck Medical Oncology and an Andrew Sabin Family Fellow at MD Anderson Cancer Center in Houston, Texas. She completed her B.A. degree in Molecular Biology at Princeton University, her M.D. at Baylor College of Medicine, and M.S. in Patient-Based Research at the University of Texas Graduate School of Biomedical Sciences. She is a member of the National Cancer Institute’s Small Cell Lung Cancer (SCLC) Consortium and serves on the NCI’s Thoracic Malignancy Steering Committee and SCLC Working Group.
Dr. Byers’ laboratory is focused on the molecular profiling of small cell lung cancer and the development of new treatments and predictive biomarkers, particularly as they pertain to drugs targeting DNA damage repair (DDR) and immunotherapy. As a direct extension of work completed in her lab, she has led multiple clinical trials for patients with lung cancer. In addition to an outstanding publication record of over 100 peer reviewed manuscripts, Dr. Byers has earned multiple honors including two AACR The Best of AACR Journals Awards, the MD Anderson President’s Recognition for Faculty Excellence - Research Excellence Award, and most recently, membership of The American Society for Clinical Investigation (ASCI).
As a physician-scientist, her landmark research led to the identification of fundamental differences in the molecular wiring of SCLC, including the identification of PARP1 and other DNA damage repair (DDR) proteins as novel therapeutic targets for SCLC. Building on this, her group also identified a new role of DDR inhibitors in activating the innate immune system, whereby dramatically enhancing response to immune checkpoint blockade in preclinical models. Recently, her team has defined molecularly distinct subtypes of SCLC that predict response to targeted therapy and immunotherapy and uncovered tumor heterogeneity as a driver of resistance using innovative, patient-derived models (published in Cancer Cell 2021 and Nature Cancer 2020).
Dr. Byers’ laboratory is focused on the molecular profiling of small cell lung cancer and the development of new treatments and predictive biomarkers, particularly as they pertain to drugs targeting DNA damage repair (DDR) and immunotherapy. As a direct extension of work completed in her lab, she has led multiple clinical trials for patients with lung cancer. In addition to an outstanding publication record of over 100 peer reviewed manuscripts, Dr. Byers has earned multiple honors including two AACR The Best of AACR Journals Awards, the MD Anderson President’s Recognition for Faculty Excellence - Research Excellence Award, and most recently, membership of The American Society for Clinical Investigation (ASCI).
As a physician-scientist, her landmark research led to the identification of fundamental differences in the molecular wiring of SCLC, including the identification of PARP1 and other DNA damage repair (DDR) proteins as novel therapeutic targets for SCLC. Building on this, her group also identified a new role of DDR inhibitors in activating the innate immune system, whereby dramatically enhancing response to immune checkpoint blockade in preclinical models. Recently, her team has defined molecularly distinct subtypes of SCLC that predict response to targeted therapy and immunotherapy and uncovered tumor heterogeneity as a driver of resistance using innovative, patient-derived models (published in Cancer Cell 2021 and Nature Cancer 2020).
Published in
Speakers
Published in
Speakers
Expertise: My main research interests are the multidisciplinary synthetic therapy on lung cancer from basic science to bedside and evidence-based medicine in oncology.
Achievement: I lead some scientific research projects including National Key Research and Development Program of China and National Natural Science Foundation of China. I participate more than 120 multicenter clinical trials in lung cancer field and acts as Principle Investigator (PI) of 28 clinical trials.
Published Articles: I published more than 70 SCI research papers in the past five years and one of them was published in Journal of Clinical Oncology (JCO) (IF=32.956).
Awards: Obtained second prize of National Scientific and Technological Progress Award, first prize of China Medical Science and technology award, first prize and second prize of Guangdong science and technology award.
Achievement: I lead some scientific research projects including National Key Research and Development Program of China and National Natural Science Foundation of China. I participate more than 120 multicenter clinical trials in lung cancer field and acts as Principle Investigator (PI) of 28 clinical trials.
Published Articles: I published more than 70 SCI research papers in the past five years and one of them was published in Journal of Clinical Oncology (JCO) (IF=32.956).
Awards: Obtained second prize of National Scientific and Technological Progress Award, first prize of China Medical Science and technology award, first prize and second prize of Guangdong science and technology award.
Published in
Speakers
Studied medicine at the University in Bergen, Norway. Trained to become a specialist in Oncology at St. Olav's Hospital, the University Hospital in Trondheim, Norway. Completed my Ph.D. at NTNU, the Norwegian University of Science and Technology, also in Trondheim. Professor in Oncology at the Department of Clinical and Molecular Medicine, NTNU, and Consultant in Oncology (both medical oncology and radiation therapy) at St. Olav's Hospital. Member of the board of the Norwegian Lung Cancer Study Group. Research activity include clinical trials and translational research on lung cancer, health related quality of life, and cancer in elderly. Most current research focuses on small-cell lung cancer.
Published in
Speakers
Carl Gay received his undergraduate degree in Biology from Johns Hopkins University. He then received both his MD and PhD, the latter in Cellular & Molecular Biology, from the New York University School of Medicine. Dr. Gay subsequently completed his clinical training in internal medicine University of Texas Health Science Center at Houston and medical oncology at the University of Texas MD Anderson Cancer Center, where he now serves as an Assistant Professor in the Department of Thoracic/Head & Neck Medical Oncology with a focus on translational research and clinical trial development for patients with small cell lung cancer
Published in
Speakers
Terufumi Kato, MD, is a chief physician at Thoracic Oncology Department in Kanagawa Cancer Center in Yokohama, Japan. Dr Kato received his medical degree from the Faculty of Medicine at Kyoto University in Japan. He served his residency in general practice and internal medicine at Tenri Hospital in Nara, Japan, after which he joined the staff physician in department of respiratory medicine of the hospital. He completed an advanced clinical fellowship in medical oncology at the National Cancer Center Hospital in Tokyo and completed a research fellowship at the National Cancer Center Research Institute, also in Tokyo. He is now a member of international society including ASCO, ESMO, IASLC, and also taking part in several committee member or faculty of Japanese society of medical oncology, Japanese lung cancer society and Japanese respiratory society. One of his main research fields is clinical research for medical treatment for lung cancer especially concerning genomic diagnosis, drug therapy for driver oncogenic cancers, and immunotherapy. Other field is management of drug induced pneumonitis in both lung cancer and other tumor treatment.
Published in
Speakers
Dr. Nishino is a Professor of Radiology at Harvard Medical School and a Thoracic Radiologist at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, with expertise in imaging of precision cancer therapy and immunotherapy. Her research is on quantitative evaluations of tumor burden dynamics and image-based profiling of toxicities during novel cancer therapy, focusing on lung cancer and pneumonitis. Her work contributes to provide objective methods for treatment monitoring in cancer patients, which forms a basis for further advancement of cancer therapy.
Published in
Speakers
Dr. Valerie Rusch has been a member of the Thoracic Surgery Service at MSKCC since March, 1989. A native New Yorker, she is a graduate of Vassar College and Columbia University College of Physicians and Surgeons. She completed her general surgery and cardiothoracic surgery residencies at the University of Washington in Seattle. After an additional year of experience in thoracic oncology at MD Anderson Cancer Center, she returned to the University of Washington where she served on the faculty for six years prior to her appointment at MSKCC. Dr. Rusch was Chief of the MSK Thoracic Service from 2000 to 2013.
Dr. Rusch’s career has been devoted to thoracic surgical oncology and clinical and translational research, especially in the fields of malignant pleural mesothelioma and lung cancer. Over a period of 35 years, she has been principal investigator for trials performed by multiple NCI-sponsored Cooperative Groups, including LCSG, SWOG, RTOG, and ACOSOG, where she also held co- and vice-chair positions. She has been heavily involved with the development of TNM Staging systems for lung cancer and malignant mesothelioma through the International Association for the Study of Lung Cancer (IASLC) and is the Chair-Elect of its International Staging and Prognostic Factors Committee. She served as Chair of the American Board of Thoracic Surgery from 2009 to 2011.
Dr. Rusch continues to have a busy clinical practice at MSKCC. In addition, she serves as Vice Chair for Clinical Research in the Department of Surgery, overseeing a large multidisciplinary clinical research program, and as Co-Chair of the Research Council, which is responsible for scientific review of all clinical trials performed at MSKCC. Over many years Dr. Rusch has held multiple leadership positions in the American College of Surgeons (ACS), the world’s largest surgical organization. Among other responsibilities she has served as Chair of the ACS Program Committee and Chair of the Board of Regents, and was the 2018 recipient of the Distinguished Service Award. During 2019-2020, she served as President of the ACS, functioning as global ambassador for the College and playing a central role in developing practice guidelines during the COVID-19 pandemic.
Dr. Rusch’s career has been devoted to thoracic surgical oncology and clinical and translational research, especially in the fields of malignant pleural mesothelioma and lung cancer. Over a period of 35 years, she has been principal investigator for trials performed by multiple NCI-sponsored Cooperative Groups, including LCSG, SWOG, RTOG, and ACOSOG, where she also held co- and vice-chair positions. She has been heavily involved with the development of TNM Staging systems for lung cancer and malignant mesothelioma through the International Association for the Study of Lung Cancer (IASLC) and is the Chair-Elect of its International Staging and Prognostic Factors Committee. She served as Chair of the American Board of Thoracic Surgery from 2009 to 2011.
Dr. Rusch continues to have a busy clinical practice at MSKCC. In addition, she serves as Vice Chair for Clinical Research in the Department of Surgery, overseeing a large multidisciplinary clinical research program, and as Co-Chair of the Research Council, which is responsible for scientific review of all clinical trials performed at MSKCC. Over many years Dr. Rusch has held multiple leadership positions in the American College of Surgeons (ACS), the world’s largest surgical organization. Among other responsibilities she has served as Chair of the ACS Program Committee and Chair of the Board of Regents, and was the 2018 recipient of the Distinguished Service Award. During 2019-2020, she served as President of the ACS, functioning as global ambassador for the College and playing a central role in developing practice guidelines during the COVID-19 pandemic.
Published in
Speakers
Professor of Surgery, Chief, Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan. Graduated from Keio University School of Medicine in 1983. Attending surgeon (Thoracic surgery, 1992-1998), Chief of Thoracic Surgery (1992-2014), and Deputy Director-Hospital (2012-2014) at the National Cancer Center Hospital, Tokyo. Professor of Surgery, Chief, Division of Thoracic Surgery, Keio University School of Medicine (2014-present). Doctor of Medical Science Degree from Keio University in 1997. IASLC activities include Chair of Staging and Prognostic Factors Committee (SPFC, 2016 - present), Executive Board Director (2012-2016), A Congress President for 18th World Conference on Lung Cancer. Vice President, Japan Lung Cancer Society.
Published in
Speakers
